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Abstract
Introduction
Approximately 3-7% of pregnancies are affected by preeclampsia 
(Sarma, et al, 2016). These pregnancies are higher risk due to the 
hypertensive effects on the mother and fetus. There are 
recommendations for preeclamptic women to take 81 mg aspirin, 
daily, for prevention of negative fetal and maternal outcomes. 
Hypertension leads to increased cardiovascular morbidity and 
mortality (Sutters, 2018). Currently, there is a lack of evidence for 
treatment beyond the post-partum period. This review investigates 
if continued aspirin therapy helps to reduce future cardiovascular 
morbidity and mortality in patients who were diagnosed with 
preeclampsia during their pregnancy. 
Research Questions
Literature Review Application to Clinical Practice
Acknowledgements
Discussion
To evaluate if preeclampsia leads to future cardiovascular risk, 
and if aspirin decreases that risk, is multi-fold. First, one must 
understand the vascular physiology of aspirin and preeclampsia. 
In regard to how preeclampsia affects endothelial health, the 
information is lacking and more studies are needed to 
differentiate which mechanisms are leading to endothelial 
dysfunction in this population. Chambers et al. (2001), Heidema 
et al. (2015) and Spaanderman et al. (2005) all found that 
preeclampsia leads to endothelial dysfunction and increased 
platelet activity. More research is necessary to determine the 
validity of these results and increase the understanding of these 
mechanisms at play. 
Aspirin has been theorized to have mechanisms interacting with 
the oxidative damage to the endothelium and decreasing 
platelet activity following endothelial injury. Hashemi et al. 
(2016), and Spaanderman et al. (2005) found that aspirin works 
by more than one mechanism to alter endothelial physiology 
and improve vascular health. Again, further research is needed 
to validate these results. 
Investigating the long term cardiovascular effects following 
preeclampsia is more of a challenge due to the longevity of a 
studied required to produce high quality results. From the 
available literature, only a few studies are of the quality and 
sample size in which to make a broad generalization to the post-
preeclamptic population. Of these, it has been found that in fact, 
these women have increased cardiovascular morbidity and 
mortality, however, not until the 3rd-5th decades following delivery 
(Funai et al., 2005, and Bokslag et al., 2017). Many of the 
available information is based on retrospective studies and 
evaluation from a hospital database. As there is variation 
amongst the studies regarding inclusion and exclusion criteria, it 
is not always clear what other variables are present in the lives 
of these subjects that may predispose them to increased 
cardiovascular morbidity and mortality. There continues to be a 
need for stronger studies as it appears there is a population that 
can benefit from preventative therapy to decrease 
cardiovascular events and thus decrease healthcare costs to 
both the patient and the healthcare system as a whole. 
When studying if aspirin is an appropriate therapy for prevention 
in this population, it is important to keep in mind that they are 
not at increased risk until later in life. Aspirin effect in an elderly 
population is warranted when weighing the risks versus benefits 
of aspirin therapy in this population. The information from Sarma 
et al. (2016), and McNeil et al. (2018) demonstrate long term 
aspirin use for primary prevention has higher risk to benefit ratio. 
It is important for future research to investigate if preeclampsia 
makes aspirin use in this population “primary” or “secondary” 
prevention. 
There are many unknown variables that need to be considered 
when trying to solve this question in regard to the post-
preeclamptic population. First, more information is needed to 
definitively determine the pathophysiology of preeclampsia. This 
understanding will guide researchers in evaluating future risks. 
Second, determination of future risk in this population. This 
research should include large, long-term studies with a diverse 
sample population. It is astute to also control for other variables 
that lead to cardiovascular disease. 
It is upon the healthcare research community to provide sound 
studies and our duty as medical professionals to better serve 
this population. Little remains known about the pathophysiology 
of this group, let alone how that affects their future risk. It is our 
duty to provide these women with the best care possible. 
• Introduction: Preeclampsia during pregnancy warrants therapy 
with low dose aspirin. The purpose of this review is to 
investigate if these women are at increased future risk for 
cardiovascular morbidity and mortality, and if aspirin therapy 
prevents future cardiovascular events. 
• Research Questions: Do women who had preeclampsia during 
pregnancy have increased future cardiovascular morbidity and 
mortality?
• Does continued aspirin use in postpartum women, who had 
preeclampsia during pregnancy, decrease future cardiovascular 
morbidity and mortality?
• Research Methods: Literature review was conducted utilizing 
CINAHL, Dynamed plus and PubMed databases. 
• Discussion: Many studies have found that preeclampsia does 
increase risk of cardiovascular morbidity and mortality, but this 
difference is not statistically significant until later decades in life. 
There is also new evidence that the risks of bleeding from 
prophylactic aspirin therapy outweigh the benefit of decreasing 
cardiovascular and ischemic events. Based on this information, 
it is prudent to further research and study this group and stratify 
their risk as well as researching if there is a better modality upon 
which to provide prophylaxis with lower risk than benefit. 
• Keywords: Aspirin, Preeclampsia, Effect on endothelium, post-
partum, future cardiovascular risk
1. Do women who had preeclampsia during pregnancy have 
increased future cardiovascular morbidity and mortality?
2. Does continued aspirin use in postpartum women, who had 
preeclampsia during pregnancy, decrease future 
cardiovascular morbidity and mortality outcomes?
Preeclampsia effect on endothelium
•Chambers et al. (2001) conducted a study designed to extrapolate maternal 
versus placental factors contributing to the development of preeclampsia. 
•Heidema et al. (2015) investigated if having history of preeclampsia versus 
obesity had a larger impact on the development of metabolic syndrome later in 
life. 
• They found the incidence of developing metabolic syndrome was 
statistically significant in those with history of preeclampsia, compared 
to those who were obese (P<0.001). 
•Spaanderman et al. (2005) found that formerly preeclamptic women had a 
15% increase in platelet responsiveness, demonstrating endothelial 
dysfunction to some degree. 
• They hypothesize that endothelial shear from the transient 
hypertension of preeclampsia increases the number of presensitized 
platelets, contributing to the hyperactive platelet activity of these 
patients. 
Aspirin effect on endothelium
•Hashemi et al. (2016) utilized flow-mediated brachial artery dilation, in a triple-
blind randomized control trial, to evaluate how aspirin affects endothelial 
function of preeclamptic patients following pregnancy. 
• They found antioxidant effects of aspirin decrease oxidative injury to 
the endothelium, decreasing platelet activation.
•The evidence by Hashemi et al. (2016), and Spaanderman et al. (2005) 
demonstrate that aspirin decreases platelet responsiveness by more than one 
mechanism. 
• Decreased endothelial shear and platelet response. 
Long term cardiovascular outcomes  
•Bokslag et al. (2017) and Funai et al. (2005), discovered formerly preeclamptic 
women are at increased future cardiovascular morbidity and mortality, starting 
in the 5th and 3rd decades (respectively) following delivery. 
• Bokslag et al. (2017) found 42% of their formerly preeclamptic 
subjects met their defined criteria to require early preventative 
measures, compared to their counterparts (P<0.0001). 
• Funai et al. (2005) had results showing in 24-36 years of follow up is 
when the risk of death more than doubled in women who were 
preeclamptic in the past. 
•Grandi et al. (2017) found formerly preeclamptic women were at higher risk of 
developing cardiovascular disease later in life, demonstrated by a hazard ratio 
of 2.2, and 95% confidence interval. 
•Leslie et al. (2016) conducted a well-defined meta-analysis in which the 
literature shows formerly preeclamptic women have a 2x increased risk of 
developing cardiovascular disease and mortality. 
• This risk is further increased with gestation longer than 37 weeks. (RR, 
0.98; 95%CI, 0.5-1.92)
•Wikstrom et al. (2005) also found statistically significant increase in future 
cardiovascular disease. 
• Wikstrom et al. (2005) utilized IRRs and 95% CI for statistical analysis 
and the adjusted IRR for ischemic disease in women with 
hypertension during multiple pregnancies was statistically significantly 
higher than women who only experienced hypertension during their 
first pregnancy (P<0.044). 
Aspirin effect on long term cardiovascular outcomes following 
preeclampsia
•Sarma et al. (2016) found there is a 12% decrease in cardiovascular events 
and 17% decrease in stroke, however, due to increased bleeding risk with 
aspirin therapy for primary prevention, the benefit of aspirin therapy was 0.3%, 
showing little benefit. 
• Aspirin use for secondary prevention shows 14% decrease in all-
cause mortality (HR 0.86).
•McNeil et al. (2018) found that aspirin use significantly decreased 
cardiovascular events (HR 0.89, 95% CI, 0.77 to 1.03). However, risk for major 
hemorrhagic events was also significantly higher in the aspirin group. 
•The findings in these two large studies demonstrate that the risk of 
hemorrhagic event from aspirin therapy outweighs the benefits when used for 
primary prevention.
•More research is necessary to further extrapolate if preeclampsia would make 
this secondary prevention. 
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Statement of the Problem
Preeclampsia involves a hypertensive state, which increases the 
shear against the endothelium of blood vessels. This predisposes 
these women to thrombotic and ischemic events. This problem is 
two-fold. One, we must understand if this group is at increased 
future risk of cardiovascular morbidity and mortality. Two, is there a 
treatment that decreases this risk. This knowledge holds the 
potential of revealing a population in which we can intervene to 
produce better cardiovascular outcomes. 
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The clinical implications of this is important as there may be a 
subset that is at increased risk that could benefit from 
preventative measures. Understanding comes two fold in this 
investigation. First, determining if this population is at increased 
future risk and second, if aspirin is the appropriate preventive 
therapy for this population. The longevity required in a study of 
this nature has potential for high drop-out rates which will skew 
results. However, this information is important as there is 
potential to decrease burden on the healthcare system and 
potential for saving healthcare dollars by preventing major 
cardiovascular events if this population has been undertreated. 
Current research remains inconclusive at this time. More studies 
are required to provide good evidence upon which to base 
practice recommendations. Determining the answers to these 
questions allows us as healthcare providers to better serve 
these patients. Not only will this knowledge and further 
understanding benefit the health of the patient, it has potential to 
decrease healthcare dollars and the burden placed on the 
healthcare system by preventing major cardiovascular events.  
